Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

Summary

A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab. In addition, patients will receive either Squalamine lactate 0.2% eye drops or Placebo eye drops. The study duration is approximately 9 months to primary endpoint

Timeline

Start

2016-04-12

Primary completion

2017-12

Completion

2017-12

Drugs

Indications